INTRODUCTION
Hepatocellular carcinoma (HCC) is the third most common cause of cancerrelated mortality worldwide and is increasing in incidence 1-3 . Intriguingly, a transcriptomic analysis of 17 different cancer types in humans revealed substantial overlap in all cancers with the exception of HCC 4 , which is consistent with the observation that treatments effective in other cancers have failed when applied to HCC 5 . HCCs are derived from hepatocytes 6 , and the unique characteristics of HCC may be related to the central role of hepatocytes in multiple metabolic processes including carbohydrate and fat storage and energy utilization, amino acid processing, bile salt synthesis recycling, protein detoxification, and drug metabolism, amongst other functions. Therefore, the development of new therapies will depend upon a better understanding and modeling of HCC.
Potentially curative interventions like liver transplantation are available to fewer than 30% of patients at the time of HCC diagnosis 7 . Sorafenib was the only first-line FDA-approved drug to treat HCC for over a decade 1, 8 . A multi-kinase inhibitor, sorafenib inhibits cell proliferation and angiogenesis through inactivation of various pathways including the ERK, VEGF, and PDGF cascades 9 . Resistance develops rapidly through numerous mechanisms leading to a median survival benefit of only 2-3 months.
There are no good predictors of response to this treatment, likely due to inherent tumor heterogeneity 9, 10 . Furthermore, sorafenib has side effects including diarrhea, fatigue, and a syndrome of hand-foot skin reaction/rash, which often requires dose reduction 9 .
Dual therapy with lower doses of sorafenib plus capecitabine 11 , doxorubicine 12 , and others 13, 14 , have not significantly improved survival and are not FDA-approved.
Recently, additional multi-kinase inhibitors (e.g. cabozantinib) with mechanisms of actions similar to sorafenib, as well as anti-angiogenesis inhibitors and immunotherapy have been approved for treatment of HCC, but none of these have been shown to have improved survival over sorafenib [15] [16] [17] [18] . Hence, there is still a need for broadly effective therapies.
Here, we report a conditional in vivo screen for drivers of tumor growth in the presence of sorafenib, designed to identify potential combination treatments for HCC.
We validate a novel drug combination -sorafenib plus Liver X Receptor alpha (LXRα) agonist -with enhanced killing of HCC. LXRα agonists are currently in clinical trials and likely have acceptable side effect profiles for patients with advanced HCC.
MATERIALS AND METHODS

Animal tumor model
We previously described our method to perform genetic screening in vivo in the Fah -/mouse model of liver injury and repopulation 19 . These mice do not normally develop HCC unless oncogenes are provided 20 . Fah -/mice were maintained on 8 mg/liter nitisinone in the drinking water until the day of hydrodynamic tail vein injection (HTVI) with 10 µg of the plasmid library, consisting of equimolar amounts of the 44 different plasmids contained in the library (43 genes-of-interest and GFP). Each cDNA in the library has a unique 5-nucleotide barcode in the 3' untranslated region to facilitate linkage of cDNAs to tumors via high-throughput sequencing. After HTVI and removal of nitisinone, mice were monitored for weight changes and overall body condition score.
Sorafenib (30 mg/kg) or a DMSO control solution was administered by gavage daily beginning 6 weeks post-HTVI and continuing to 15 weeks. Magnetic resonance imaging (MRI) was performed at the Penn Small Animal Imaging Facility immediately after euthanasia. All procedures were approved by our institutional animal care and usage committee.
Tumor sequencing
Whole livers from mice receiving the plasmid library were fixed overnight in 4% paraformaldehyde, mounted in paraffin, serially sectioned, and stained with hematoxylin and eosin by the University of Pennsylvania Molecular Pathology and Imaging Core.
Hematoxylin and eosin-stained sections were submitted to the University of Pennsylvania School of Veterinary Medicine Comparative Pathology Core for histological grading and calling of HCC lesions based upon guidelines 21 , and the pathologist was blinded to study conditions. The HCC tissue from unique lesions was collected from adjacent serial sections using a fine needle and a stereo microscope.
This tissue was used directly for two rounds of PCR using primers flanking the area of the 5-nucleotide barcode as described previously 19 . Sequencing libraries from each tumor received a unique Illumina index to enable multiplexing, and sequencing was conducted on an Illumina MiSeq by the University of Pennsylvania Next Generation Sequencing Core. A detailed protocol is available upon request.
Cell culture
Hep3B, Hepa1-6, HepG2, and AML12 cell lines were purchased from ATCC.
Huh7 were purchased from JCRB Cell Bank through Sekisui XenoTech company.
Hep3B, Hepa1-6, HepG2, and Huh7 were cultured in DMEM with 10% fetal bovine serum and 5% Penicillin/Streptomycin. AML12 was cultured in DMEM:F12 supplemented with 10% FBS, 10 µg/ml insulin, 5.5 µg/ml transferrin, 5 ng/ml selenium, and 40 ng/ml dexamethasone. The PGM898 cell line is a patient-derived cell line that was generated by xenografting immunodeficient mice with percutaneous core biopsy HCC tissue, then culturing dispersed cells from the tumor (University of Pennsylvania Institutional Review Board-approved observational clinical trial #825782; Ackerman, D., et al., manuscript in preparation) . The patient was a male in his 50s with HCV cirrhosis and BCLC stage B HCC. Pathology of biopsies taken at the time of sample procurement demonstrated moderately differentiated HCC. After establishment of the cell line, cells were propagated on Matrigel-coated plates in DMEM:F12 with 10% FBS, 5% P/S, Glutamax, Hepes, and 10 μ M ROCK inhibitor.
Drug treatments and crystal violet staining
Sorafenib, GW3965, and T0901317 were prepared in DMSO. For drug treatments, 9 x 10 4 cells were seeded in wells of a 24 well plate (or 10 5 AML12 cells in 6-well plates), and the following day the drugs or DMSO were added in fresh media.
Forty-eight or 72 hours after treatment, cells were washed with PBS, fixed with 4% PFA, and stained with 0.05% crystal violet for 20 minutes. Once plates were washed, dried and imaged, methanol was added and absorbance was measured at 540nm.
RNA sequencing
Huh7 and Hep3B were seeded at 6 x 10 5 cells in 6-well plates. Wells were treated with DMSO, 2 µM sorafenib, 5 µM GW3965, or 2 µM sorafenib plus 5 µM GW3965 (combination group). Twenty-four hours later, RNA was extracted (Qiagen RNeasy mini kit) and purity was confirmed using an Agilent Bioanalyzer. Following enrichment of mRNA using magnetic bead isolation of poly(A) sequences (NEB #E7490), we prepared sequencing libraries using a commercial kit (NEB #E7770S).
Sequencing was performed on a HiSeq 4000. Differential expression analysis was performed using edgeR (R software). To create a heatmap, we calculated the Log2 fold change (Log 2 FC) of each sample normalized to the average values in the DMSO treatment group, then subtracted the median Log 2 FC value of the DMSO group. This DMSO-centered Log 2 FC was plotted using ComplexHeatmap (R software). Gene ontology (GO) pathway analysis was performed using package STRINGdb, and visualized with ggplot2 and stringr (R software). RNA-seq data was submitted to the Gene Expression Omnibus (GEO, accession # pending).
RT-PCR analysis
PGM898 cells were treated for 24 hours and RNA was extracted as described above. Reverse transcription was performed with the High-Capacity cDNA Reverse Transcription Kit (Thermo-Fisher). qPCR was performed using Sybr green and the following primers: GAPDH Forward: GTCTCCTCTGACTTCAACAGCG, GAPDH AGGCTTGCACGTTGAGTTTG. For analysis, threshold cycle values were normalized to the average threshold cycle for GAPDH and B2M.
Statistical analysis
All scatter plots and bar graphs independent of RNA sequencing data were created using GraphPad. Statistical analyses were performed using a two-way ANOVA with Tukey's test for multiple comparisons, a one-way ANOVA with multiple comparisons, or a Student's t-test, as distinguished in the figure legends.
RESULTS
Generation of an HCC model using a plasmid library
We previously engineered a library of 43 cDNAs important in liver growth and function, which are expressed from plasmids also encoding the FAH enzyme. This plasmid pool was hydrodynamically injected into the tail vein of Fah -/mice to identify drivers of liver repopulation 19 . We previously identified MYC as a potent driver of liver repopulation, and TNFR1 as a strong negative regulator of liver repopulation. Liver tumors develop rapidly in this model, as evidenced by the fact that plasmid libraryinjected Fah -/mice developed neoplasms as early as six weeks post-injection ( Figure   1A , B). The tumors displayed significant heterogeneity and were confirmed to be HCC by a veterinary pathologist. We determined the putative HCC driver genes present in each tumor by performing high-throughput sequencing of the linked DNA barcodes present in isolated tumor nodules ( Figure 1C , D). We found an median of 4 distinct cDNAs per HCC tumor (range 1-11). Moreover, when we sequenced DNA from multiple parts of the same tumor, we found the same cDNA composition, indicating that tumors 1 0 are clonal ( Figure 1D , black box). Remarkably, all HCCs contained the Myc cDNA, indicating that MYC was the most potent driver of tumorigenesis among all the genes tested.
Sorafenib-resistant tumors cannot grow in the presence of Nr1H3 (encodes LXR)
We hypothesized that our screening approach could be used to discover genes that confer sensitivity or resistance to sorafenib. Therefore, we injected Fah -/mice with the plasmid library, and allowed the mice to repopulate their livers for six weeks, the time-point at which early tumors are established. We then began daily treatment with either 30 mg/kg sorafenib or vehicle control for two months (Figure 2A ). Sorafenib treatment significantly reduced the liver weight to body weight ratio and tumor burden compared to vehicle ( Figure 2B , C). Intriguingly, sorafenib-resistant tumors had a higher mitotic index than vehicle tumors ( Figure 2C ).
To identify genes correlated with sorafenib sensitivity, we analyzed which cDNA(s) were present or absent in HCCs that developed in the presence of sorafenib.
Strikingly, we detected the Myc oncogene in all vehicle-and sorafenib-treated tumors assessed. However, the Nr1h3 transgene, which encodes LXRα, was present in a number of vehicle-treated tumors as expected ( Figure 1D , 3A). Intriguingly, it was completely absent from sorafenib-resistant tumors ( Figure 3A, B) . These results indicate that high LXR activity is incompatible with MYC-driven tumor growth in the presence of sorafenib.
LXR agonists improve sorafenib efficacy against HCC in vitro
Based on our in vivo results, we asked whether activating LXR within cells using agonist drugs would improve response to sorafenib. We treated three human hepatoma cell lines (Hep3B, HepG2, and Huh7) and one murine hepatoma cell line (Hepa1-6) with varying doses of sorafenib and the small-molecule LXR agonist GW3965. We quantified cell viability after 48 hours by crystal violet staining ( Figure 4 ). In each cell line, there was a 30-50% reduction in cell viability with the combination treatment at a minimal dose of 5 µM GW3965 and 2 µM sorafenib compared to sorafenib-only treatment, while treatment with 5 µM GW3965 alone did not affect cell viability ( Figure 4B , D, E, G). At these doses, neither GW3965 nor sorafenib treatment alone impacted the murine hepatocyte-derived cell line AML12, whereas combination treatment led to only a 20% reduction from baseline (Supp. Figure 1A, B ), suggesting treatment preferentially affects HCC cells. We also confirmed our findings in HepG2, Hep3B, and Huh7 cells using a second LXR agonist, T0901317, confirming that activation of LXR enhances sorafenib activity (Supp. Figure 1C , D). Taken together, these results suggest that LXR activation improves the efficiency of sorafenib in multiple HCC cell lines.
GW3965 and sorafenib work synergistically to target numerous pathways in vitro
We queried the mechanism by which the combination treatment targets HCC, and performed RNA sequencing in Hep3B and Huh7 cells treated with drugs for 24 hours. Principle component analysis identified clear separations between cell lines and treatment groups ( Figure 5A ). Next, we performed differential expression analysis comparing treatment to DMSO control groups, using a cut-off fold change of >2 (Log 2 FC >1 or <-1, Figure 5B ). We found many genes to be altered by treatment in both cell lines congruently: 19 genes were differentially expressed in response to GW3965, 190 to sorafenib, and 915 to the combination treatment, overall highlighting a remarkable synergistic effect as visualized in Figure 5B .
Next, we confirmed the specificity of sorafenib and GW3965 treatment by assessing gene expression levels of known markers of drug activity. Upregulation of GADD45B and downregulation of PDGFRB mRNA levels are indicative of sorafenib activity 22, 23 , and we observed these trends in sorafenib and combination groups. We also noted upregulation of the LXR target genes FASN and SREBF1 24, 25 in the GW3965 and combination groups, as expected ( Figure 5C ).
Combination treatment inhibits the cell cycle and increases apoptosis
Next, we performed pathway analysis of the 915 differentially expressed genes in the combination group and found 472 gene ontology (GO) pathways to be significantly altered. The top ten altered pathways, based on gene ratio, are displayed in Figure 5D .
The most dramatically altered GO pathway was regulation of cell death, with several others also relating to cell cycle and apoptosis, boxed in red in Figure 5D . When investigating steady state mRNA levels of cell cycle and apoptotic regulators, we found downregulation of many proliferation markers such as Origin Recognition Complex Subunit 1 (ORC1), Cell division cycle 25 A, (CDC25A), various cyclins (CCNB1, CCNE1), Minichromosome maintenance complex proteins (MCM2, MCM5), proliferating cell nuclear antigen (PCNA), cyclin-dependent kinase 2 (CDK2), and marker of proliferation Ki67 (MIK67) ( Figure 6A ). Moreover, we noted upregulation of many genes Figure 6B ). Sorafenib monotherapy also led to a moderate reduction in cell cycle and upregulation in apoptosis markers; although these effects were much more pronounced in combination therapy, again highlighting the cooperative effects of GW3965 and sorafenib.
Combination therapy effectively targets a patient-derived HCC
We obtained a core biopsy-derived cell line of an HCC lesion from a patient, who died 3 weeks after initiating sorafenib. We found that sorafenib monotherapy had low activity at killing this cell line, reducing viability by only 20% at the highest dose, indicating sorafenib resistance. However, when we applied the GW3965 and sorafenib combination therapy, we killed the tumor cells with similar efficiency as seen with the HCC cell lines ( Figure 7A, B ). Next, we extracted RNA from cells 24 hours after treatment, and observed increased transcript levels of FASN in GW3965 and combination treatments, and increased GADD45B in sorafenib and combination treatments, indicating that the combination therapy had cooperative effects on the same pathways as we observed in commercial cell lines ( Figure 7C ). Importantly, we found markedly reduced expression of the cell cycle promoters CDK2, CCNE1, and PCNA in the combination group ( Figure 7D ). Our results demonstrate that LXR agonist/sorafenib combination therapy effectively kills primary HCC cells, highlights the preclinical relevance of our studies, and suggests that drug therapy assays could be used in future personalized medicine treatment plans.
DISCUSSION
In this study, we employed a novel genetic screen that identified LXR as a druggable target to increase the anti-tumor effect of sorafenib. Our screen utilized a previously described library of cDNAs of interest, together with the Fah cDNA, hydrodynamically-injected into the tail vein of Fah -/mice 19 . This model develops HCC within 6 weeks. We identified LXR to be disallowed in sorafenib-resistant tumors, and found that the combination of LXR agonists with sorafenib effectively kills HCC cells in vitro through downregulation of the cell cycle and upregulation of markers of apoptosis.
The LXR agonists GW3965 and T0901317 are known to induce conformational changes to LXR that enhances binding to coactivators. While these compounds also have an affinity for LXRß, the K d values are dramatically lower for LXRα 26 . GW3965
appears to be more potent in vitro in combination with sorafenib, as a significant effect was observed at 48 hours (as opposed to 72 hours with T0901317) and at lower doses.
Consistently across cell lines, we witnessed a significant reduction in cell viability with 5 µM GW3965 and 2 µM sorafenib. At these doses, cell viability dropped to approximately 50% in all transformed cells, but remained at 80% in the mouse hepatic cell line AML12.
These findings suggest that the combination treatment preferentially kills cancer cells and spares non-cancerous cells, and could be used to reduce sorafenib dose to reduce toxicity in vivo.
The synergistic impact of GW3965 and sorafenib combinatorial treatment on gene expression is visualized in our heatmap in Figure 5B . While we noted cell linespecific variability, the combination treatment clearly led to similar transcriptomic changes. It is interesting that in Hep3B cells, sorafenib monotherapy led to similar changes in gene expression as the drug combination, whereas in Huh7 the sorafenib condition mostly clustered separately from the combination group. Multiple studies have found that Hep3B are more sensitive to sorafenib than Huh7 27-29 . These data, combined with our data from a sorafenib monotherapy-resistant primary HCC cell line derived from a patient, suggest that addition of GW3965 to sorafenib overcomes sorafenib resistance in HCC.
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